Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
📰 Registry Study News
Page 2 - Registry Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Registry Study. Real-time updates on events, politics, business and more.
Kapruvia® approved in Switzerland with additional
Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated...
United Kingdom Christopher Posner Iris Francesconi Thomas Hutter Klaus Henning Jensen Annie Spinetta
Source: globenewswire.com
Vifor Pharma Group: Kapruvia approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients First launches
Source: finanznachrichten.de
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patientsAD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LRFirst approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patientsFirst launches in Europe expe...
Vifor Pharma Klaus Henning Jensen Joana Goncalves Swiss Stock Exchange European Commission Drug Administration
Source: pharmiweb.com
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Committee for Medicinal Products for Human Use recommends approval of Kapruvia® as first therapy in Europe for the treatment of chronic kidney... | February 28, 2022
United States Christopher Posner Vifor Pharma Klaus Henning Jensen International Journal Of Nephrology Cara Therapeutics Inc
Source: marketscreener.com
Vifor Pharma Group: Kapruvia receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia(difelikefalin) as first therapy in Europe for the treatment of
Source: finanznachrichten.de
Drug-Eluting Stent Promising in Intracranial Atherosclerosis?
Interest in stenting for the treatment of symptomatic high-grade intracranial atherosclerosis may be rekindled after the results of a new trial using a drug-eluting stent.
United States Wengui Yu University Of California Registry Study Symptomatic Intracranial Artery Stenosis Wingspan Stent System Post Market Surveillance
Source: medscape.com